Share Price and Basic Stock Data
Last Updated: December 12, 2025, 4:58 pm
| PEG Ratio | -12.21 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aarti Drugs Limited, a key player in the Indian pharmaceuticals sector, has seen its market capitalization hover around ₹3,631 Cr, with its stock price currently at ₹398. The company’s revenue trajectory has been mixed in recent quarters. For instance, sales peaked at ₹696 Cr in March 2023 but have since experienced fluctuations, dropping to ₹578 Cr in September 2023 and further to ₹538 Cr by December 2023. This inconsistency raises questions about demand stability in its core markets. Over the fiscal years, revenues have shown some growth, reaching ₹2,498 Cr in FY 2023, although this figure is projected to decline to ₹2,174 Cr in FY 2025. Overall, Aarti Drugs appears to be navigating a challenging environment, with a need to bolster its sales momentum to maintain a competitive edge.
Profitability and Efficiency Metrics
When examining profitability, Aarti Drugs presents a mixed picture. The operating profit margin (OPM) has fluctuated, recorded at 11% in FY 2025, which is relatively lower compared to previous years. This decline from a peak OPM of 21% in FY 2021 raises concerns about cost management and pricing strategies, especially given that expenses also rose significantly in line with sales. The company reported a net profit of ₹179 Cr, translating to a net profit margin of 7.04% in FY 2025. Furthermore, efficiency metrics like the cash conversion cycle (CCC) stood at 127 days, suggesting that the company takes a considerable amount of time to convert its investments into cash flow. While Aarti Drugs maintains a decent return on equity (ROE) of 12.28%, it must enhance its operational efficiency to drive better profitability in the long run.
Balance Sheet Strength and Financial Ratios
Aarti Drugs’ balance sheet reflects a stable financial position, with total borrowings at ₹440 Cr and reserves amounting to ₹1,250 Cr as of September 2025. The debt-to-equity ratio stands at a comfortable 0.44, indicating that the company is not overly reliant on debt financing, which is reassuring for investors. The interest coverage ratio (ICR) is notably strong at 8.46, suggesting that Aarti Drugs can comfortably meet its interest obligations. However, the company’s asset turnover ratio has seen a decline, currently at 0.95, indicating that it may not be leveraging its assets as effectively as it could. This, coupled with a declining return on capital employed (ROCE) of 14.25%, suggests that while the financial structure is sound, the company has room for improvement in asset utilization and overall returns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aarti Drugs reveals a majority promoter holding of 54.72%, which provides a level of stability to the stock. However, it is worth noting that promoter shareholding has gradually decreased from 59.66% in December 2022, potentially signaling a dilution of confidence or a strategic shift. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold a modest 2.68% and 9.90% respectively, indicating a cautious approach from institutional players. The public shareholding is substantial at 32.70%, reflecting a healthy level of retail participation. The total number of shareholders has seen a decline, which could be a point of concern, as it may indicate waning investor interest. This mixed sentiment underscores the need for Aarti Drugs to enhance its operational performance to regain and bolster investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Aarti Drugs faces a blend of opportunities and challenges. The company must address its revenue fluctuations and improve operational efficiency to drive profitability. Risks include the declining sales trend, potential cost increases, and the evolving regulatory landscape in the pharmaceutical sector, which could impact margins. Furthermore, the gradual decrease in promoter shareholding may create uncertainty among investors. However, Aarti Drugs’ solid balance sheet and decent interest coverage offer a buffer against financial distress. Investors would do well to watch how the company navigates these challenges, particularly in enhancing its sales and maintaining cost discipline. Overall, while the fundamentals provide a foundation, the path forward will require strategic execution and a focus on operational excellence to ensure sustainable growth and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,246 Cr. | 390 | 479/192 | 87.9 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,475.87 Cr | 1,158.06 | 51.79 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 551 | 625 | 626 | 696 | 592 | 578 | 538 | 560 | 493 | 543 | 515 | 623 | 521 |
| Expenses | 496 | 555 | 557 | 608 | 520 | 512 | 478 | 490 | 439 | 484 | 454 | 534 | 457 |
| Operating Profit | 55 | 70 | 69 | 89 | 72 | 65 | 60 | 69 | 54 | 60 | 60 | 89 | 64 |
| OPM % | 10% | 11% | 11% | 13% | 12% | 11% | 11% | 12% | 11% | 11% | 12% | 14% | 12% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 11 | 2 | 0 |
| Interest | 7 | 8 | 9 | 8 | 8 | 8 | 7 | 8 | 7 | 7 | 8 | 7 | 7 |
| Depreciation | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Profit before tax | 36 | 50 | 49 | 69 | 53 | 47 | 43 | 50 | 35 | 41 | 52 | 71 | 45 |
| Tax % | 28% | 27% | 25% | 23% | 25% | 26% | 26% | 27% | 23% | 26% | 26% | 13% | -7% |
| Net Profit | 26 | 37 | 37 | 53 | 40 | 35 | 32 | 36 | 27 | 30 | 39 | 61 | 49 |
| EPS in Rs | 2.85 | 3.95 | 3.96 | 5.74 | 4.27 | 3.76 | 3.44 | 3.93 | 2.93 | 3.31 | 4.19 | 6.69 | 5.29 |
Last Updated: August 2, 2025, 12:55 am
Below is a detailed analysis of the quarterly data for Aarti Drugs Limited based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 521.00 Cr.. The value appears to be declining and may need further review. It has decreased from 623.00 Cr. (Mar 2025) to 521.00 Cr., marking a decrease of 102.00 Cr..
- For Expenses, as of Jun 2025, the value is 457.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 534.00 Cr. (Mar 2025) to 457.00 Cr., marking a decrease of 77.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 89.00 Cr. (Mar 2025) to 64.00 Cr., marking a decrease of 25.00 Cr..
- For OPM %, as of Jun 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 12.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
- For Depreciation, as of Jun 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 45.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Mar 2025) to 45.00 Cr., marking a decrease of 26.00 Cr..
- For Tax %, as of Jun 2025, the value is -7.00%. The value appears to be improving (decreasing) as expected. It has decreased from 13.00% (Mar 2025) to -7.00%, marking a decrease of 20.00%.
- For Net Profit, as of Jun 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 61.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 12.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.29. The value appears to be declining and may need further review. It has decreased from 6.69 (Mar 2025) to 5.29, marking a decrease of 1.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:48 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 972 | 1,087 | 1,076 | 1,089 | 1,140 | 1,454 | 1,635 | 1,915 | 2,251 | 2,498 | 2,267 | 2,174 | 2,202 |
| Expenses | 822 | 915 | 900 | 910 | 955 | 1,252 | 1,387 | 1,511 | 1,930 | 2,212 | 1,998 | 1,908 | 1,929 |
| Operating Profit | 150 | 172 | 176 | 179 | 185 | 203 | 248 | 404 | 321 | 286 | 269 | 265 | 272 |
| OPM % | 15% | 16% | 16% | 16% | 16% | 14% | 15% | 21% | 14% | 11% | 12% | 12% | 12% |
| Other Income | 1 | 1 | 0 | 4 | 1 | 6 | 9 | 7 | 5 | 2 | 4 | 14 | 14 |
| Interest | 37 | 42 | 47 | 38 | 36 | 41 | 36 | 26 | 23 | 36 | 33 | 32 | 29 |
| Depreciation | 28 | 31 | 36 | 37 | 38 | 40 | 47 | 48 | 47 | 47 | 48 | 48 | 48 |
| Profit before tax | 86 | 100 | 93 | 108 | 112 | 128 | 175 | 338 | 256 | 205 | 192 | 199 | 209 |
| Tax % | 28% | 22% | 29% | 30% | 35% | 32% | 22% | 24% | 24% | 25% | 26% | 21% | |
| Net Profit | 62 | 78 | 66 | 75 | 73 | 87 | 136 | 258 | 195 | 153 | 142 | 157 | 179 |
| EPS in Rs | 6.38 | 8.01 | 6.84 | 7.91 | 7.78 | 9.25 | 14.56 | 27.65 | 21.06 | 16.50 | 15.43 | 17.11 | 19.48 |
| Dividend Payout % | 26% | 41% | 25% | 3% | 3% | 3% | 3% | 9% | 5% | 6% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.81% | -15.38% | 13.64% | -2.67% | 19.18% | 56.32% | 89.71% | -24.42% | -21.54% | -7.19% | 10.56% |
| Change in YoY Net Profit Growth (%) | 0.00% | -41.19% | 29.02% | -16.30% | 21.84% | 37.14% | 33.38% | -114.12% | 2.88% | 14.35% | 17.75% |
Aarti Drugs Limited has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 4% |
| 3 Years: | -7% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -8% |
| 3 Years: | 3% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 18% |
| 3 Years: | 13% |
| Last Year: | 13% |
Last Updated: September 4, 2025, 10:00 pm
Balance Sheet
Last Updated: December 4, 2025, 12:53 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 | 91 |
| Reserves | 239 | 279 | 326 | 363 | 410 | 495 | 598 | 766 | 880 | 1,022 | 1,083 | 1,160 | 1,250 |
| Borrowings | 342 | 435 | 465 | 448 | 517 | 471 | 378 | 336 | 519 | 535 | 475 | 516 | 440 |
| Other Liabilities | 257 | 228 | 240 | 281 | 366 | 384 | 471 | 442 | 543 | 546 | 522 | 506 | 463 |
| Total Liabilities | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 | 2,172 | 2,273 | 2,245 |
| Fixed Assets | 373 | 431 | 463 | 542 | 564 | 586 | 612 | 631 | 649 | 634 | 722 | 761 | 970 |
| CWIP | 8 | 13 | 34 | 14 | 28 | 32 | 11 | 16 | 60 | 161 | 222 | 273 | 92 |
| Investments | 5 | 11 | 11 | 18 | 17 | 19 | 20 | 24 | 28 | 29 | 30 | 42 | 53 |
| Other Assets | 464 | 511 | 547 | 541 | 707 | 736 | 828 | 966 | 1,297 | 1,372 | 1,198 | 1,196 | 1,130 |
| Total Assets | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 | 2,172 | 2,273 | 2,245 |
Below is a detailed analysis of the balance sheet data for Aarti Drugs Limited based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 91.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,250.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,160.00 Cr. (Mar 2025) to 1,250.00 Cr., marking an increase of 90.00 Cr..
- For Borrowings, as of Sep 2025, the value is 440.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 516.00 Cr. (Mar 2025) to 440.00 Cr., marking a decrease of 76.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 463.00 Cr.. The value appears to be improving (decreasing). It has decreased from 506.00 Cr. (Mar 2025) to 463.00 Cr., marking a decrease of 43.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,245.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,273.00 Cr. (Mar 2025) to 2,245.00 Cr., marking a decrease of 28.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 970.00 Cr.. The value appears strong and on an upward trend. It has increased from 761.00 Cr. (Mar 2025) to 970.00 Cr., marking an increase of 209.00 Cr..
- For CWIP, as of Sep 2025, the value is 92.00 Cr.. The value appears to be declining and may need further review. It has decreased from 273.00 Cr. (Mar 2025) to 92.00 Cr., marking a decrease of 181.00 Cr..
- For Investments, as of Sep 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 11.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,130.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,196.00 Cr. (Mar 2025) to 1,130.00 Cr., marking a decrease of 66.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,245.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,273.00 Cr. (Mar 2025) to 2,245.00 Cr., marking a decrease of 28.00 Cr..
Notably, the Reserves (1,250.00 Cr.) exceed the Borrowings (440.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -192.00 | -263.00 | -289.00 | -269.00 | -332.00 | -268.00 | -130.00 | 68.00 | -198.00 | -249.00 | -206.00 | -251.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 103 | 109 | 93 | 117 | 110 | 104 | 96 | 115 | 117 | 104 | 118 |
| Inventory Days | 71 | 77 | 87 | 101 | 132 | 86 | 107 | 125 | 120 | 102 | 107 | 106 |
| Days Payable | 84 | 75 | 85 | 91 | 125 | 86 | 110 | 94 | 103 | 89 | 96 | 97 |
| Cash Conversion Cycle | 91 | 105 | 110 | 103 | 124 | 109 | 101 | 127 | 133 | 130 | 115 | 127 |
| Working Capital Days | -10 | 13 | 21 | 26 | 33 | 46 | 60 | 83 | 68 | 73 | 79 | 79 |
| ROCE % | 22% | 21% | 18% | 17% | 17% | 17% | 20% | 33% | 21% | 15% | 14% | 14% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 6,387,722 | 1.86 | 313.7 | 4,636,377 | 2025-12-07 00:37:57 | 37.77% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,488,255 | 1.14 | 73.09 | N/A | N/A | N/A |
| DSP Healthcare Fund | 852,155 | 1.33 | 41.85 | 737,671 | 2025-12-07 01:59:04 | 15.52% |
| DSP Value Fund | 70,308 | 0.29 | 3.45 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 18.35 | 18.56 | 17.97 | 22.12 | 30.09 |
| Diluted EPS (Rs.) | 18.35 | 18.56 | 17.97 | 22.12 | 30.09 |
| Cash EPS (Rs.) | 24.53 | 24.26 | 23.40 | 27.54 | 35.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 149.99 | 139.40 | 128.77 | 111.91 | 98.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 149.99 | 139.40 | 128.77 | 111.91 | 98.00 |
| Revenue From Operations / Share (Rs.) | 261.54 | 275.04 | 293.31 | 268.75 | 231.20 |
| PBDIT / Share (Rs.) | 33.24 | 34.86 | 33.24 | 36.80 | 47.38 |
| PBIT / Share (Rs.) | 27.13 | 29.26 | 27.81 | 31.39 | 42.03 |
| PBT / Share (Rs.) | 23.20 | 25.62 | 24.21 | 29.15 | 39.59 |
| Net Profit / Share (Rs.) | 18.42 | 18.66 | 17.97 | 22.14 | 30.09 |
| NP After MI And SOA / Share (Rs.) | 18.42 | 18.65 | 17.96 | 22.14 | 30.09 |
| PBDIT Margin (%) | 12.71 | 12.67 | 11.33 | 13.69 | 20.49 |
| PBIT Margin (%) | 10.37 | 10.64 | 9.47 | 11.68 | 18.18 |
| PBT Margin (%) | 8.87 | 9.31 | 8.25 | 10.84 | 17.12 |
| Net Profit Margin (%) | 7.04 | 6.78 | 6.12 | 8.23 | 13.01 |
| NP After MI And SOA Margin (%) | 7.04 | 6.77 | 6.12 | 8.23 | 13.01 |
| Return on Networth / Equity (%) | 12.28 | 13.37 | 13.94 | 19.78 | 30.69 |
| Return on Capital Employeed (%) | 14.25 | 16.43 | 17.29 | 22.92 | 33.46 |
| Return On Assets (%) | 6.53 | 7.04 | 6.86 | 9.28 | 15.87 |
| Long Term Debt / Equity (X) | 0.20 | 0.21 | 0.17 | 0.13 | 0.16 |
| Total Debt / Equity (X) | 0.44 | 0.43 | 0.50 | 0.51 | 0.33 |
| Asset Turnover Ratio (%) | 0.95 | 1.04 | 1.17 | 1.18 | 1.19 |
| Current Ratio (X) | 1.60 | 1.66 | 1.60 | 1.48 | 1.77 |
| Quick Ratio (X) | 1.03 | 1.05 | 1.05 | 0.92 | 1.08 |
| Inventory Turnover Ratio (X) | 4.98 | 3.14 | 3.39 | 3.37 | 3.15 |
| Dividend Payout Ratio (NP) (%) | 5.42 | 5.36 | 5.56 | 4.51 | 8.30 |
| Dividend Payout Ratio (CP) (%) | 4.07 | 4.12 | 4.27 | 3.63 | 7.05 |
| Earning Retention Ratio (%) | 94.58 | 94.64 | 94.44 | 95.49 | 91.70 |
| Cash Earning Retention Ratio (%) | 95.93 | 95.88 | 95.73 | 96.37 | 92.95 |
| Interest Coverage Ratio (X) | 8.46 | 9.56 | 9.25 | 16.42 | 19.24 |
| Interest Coverage Ratio (Post Tax) (X) | 5.69 | 6.12 | 6.00 | 10.88 | 13.20 |
| Enterprise Value (Cr.) | 3706.38 | 4541.99 | 3725.82 | 4488.49 | 6770.51 |
| EV / Net Operating Revenue (X) | 1.55 | 1.80 | 1.37 | 1.80 | 3.14 |
| EV / EBITDA (X) | 12.22 | 14.17 | 12.10 | 13.17 | 15.33 |
| MarketCap / Net Operating Revenue (X) | 1.30 | 1.58 | 1.15 | 1.60 | 3.01 |
| Retention Ratios (%) | 94.57 | 94.63 | 94.43 | 95.48 | 91.69 |
| Price / BV (X) | 2.27 | 3.11 | 2.62 | 3.83 | 7.09 |
| Price / Net Operating Revenue (X) | 1.30 | 1.58 | 1.15 | 1.60 | 3.01 |
| EarningsYield | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 |
After reviewing the key financial ratios for Aarti Drugs Limited, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 18.35. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 18.35, marking a decrease of 0.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 18.35. This value is within the healthy range. It has decreased from 18.56 (Mar 24) to 18.35, marking a decrease of 0.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.53. This value is within the healthy range. It has increased from 24.26 (Mar 24) to 24.53, marking an increase of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 149.99. It has increased from 139.40 (Mar 24) to 149.99, marking an increase of 10.59.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 149.99. It has increased from 139.40 (Mar 24) to 149.99, marking an increase of 10.59.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 261.54. It has decreased from 275.04 (Mar 24) to 261.54, marking a decrease of 13.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 33.24. This value is within the healthy range. It has decreased from 34.86 (Mar 24) to 33.24, marking a decrease of 1.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 27.13. This value is within the healthy range. It has decreased from 29.26 (Mar 24) to 27.13, marking a decrease of 2.13.
- For PBT / Share (Rs.), as of Mar 25, the value is 23.20. This value is within the healthy range. It has decreased from 25.62 (Mar 24) to 23.20, marking a decrease of 2.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.42. This value is within the healthy range. It has decreased from 18.66 (Mar 24) to 18.42, marking a decrease of 0.24.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 18.42. This value is within the healthy range. It has decreased from 18.65 (Mar 24) to 18.42, marking a decrease of 0.23.
- For PBDIT Margin (%), as of Mar 25, the value is 12.71. This value is within the healthy range. It has increased from 12.67 (Mar 24) to 12.71, marking an increase of 0.04.
- For PBIT Margin (%), as of Mar 25, the value is 10.37. This value is within the healthy range. It has decreased from 10.64 (Mar 24) to 10.37, marking a decrease of 0.27.
- For PBT Margin (%), as of Mar 25, the value is 8.87. This value is below the healthy minimum of 10. It has decreased from 9.31 (Mar 24) to 8.87, marking a decrease of 0.44.
- For Net Profit Margin (%), as of Mar 25, the value is 7.04. This value is within the healthy range. It has increased from 6.78 (Mar 24) to 7.04, marking an increase of 0.26.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.04. This value is below the healthy minimum of 8. It has increased from 6.77 (Mar 24) to 7.04, marking an increase of 0.27.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.28. This value is below the healthy minimum of 15. It has decreased from 13.37 (Mar 24) to 12.28, marking a decrease of 1.09.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.25. This value is within the healthy range. It has decreased from 16.43 (Mar 24) to 14.25, marking a decrease of 2.18.
- For Return On Assets (%), as of Mar 25, the value is 6.53. This value is within the healthy range. It has decreased from 7.04 (Mar 24) to 6.53, marking a decrease of 0.51.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.20, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 0.44, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.95. It has decreased from 1.04 (Mar 24) to 0.95, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.60. This value is within the healthy range. It has decreased from 1.66 (Mar 24) to 1.60, marking a decrease of 0.06.
- For Quick Ratio (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 1.05 (Mar 24) to 1.03, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.98. This value is within the healthy range. It has increased from 3.14 (Mar 24) to 4.98, marking an increase of 1.84.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.42. This value is below the healthy minimum of 20. It has increased from 5.36 (Mar 24) to 5.42, marking an increase of 0.06.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.07. This value is below the healthy minimum of 20. It has decreased from 4.12 (Mar 24) to 4.07, marking a decrease of 0.05.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.58. This value exceeds the healthy maximum of 70. It has decreased from 94.64 (Mar 24) to 94.58, marking a decrease of 0.06.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.93. This value exceeds the healthy maximum of 70. It has increased from 95.88 (Mar 24) to 95.93, marking an increase of 0.05.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 9.56 (Mar 24) to 8.46, marking a decrease of 1.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.69. This value is within the healthy range. It has decreased from 6.12 (Mar 24) to 5.69, marking a decrease of 0.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,706.38. It has decreased from 4,541.99 (Mar 24) to 3,706.38, marking a decrease of 835.61.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has decreased from 1.80 (Mar 24) to 1.55, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 12.22. This value is within the healthy range. It has decreased from 14.17 (Mar 24) to 12.22, marking a decrease of 1.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.58 (Mar 24) to 1.30, marking a decrease of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 94.57. This value exceeds the healthy maximum of 70. It has decreased from 94.63 (Mar 24) to 94.57, marking a decrease of 0.06.
- For Price / BV (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has decreased from 3.11 (Mar 24) to 2.27, marking a decrease of 0.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has decreased from 1.58 (Mar 24) to 1.30, marking a decrease of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Drugs Limited:
- Net Profit Margin: 7.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.25% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.28% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.69
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.03
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.9 (Industry average Stock P/E: 42.61)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 198, M.I.D.C., Palghar District Maharashtra 401506 | investorrelations@aartidrugs.com http://www.aartidrugs.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Chandrakant V Gogri | Chairman Emeritus |
| Mr. Prakash M Patil | Chairman & M.D & CEO |
| Mr. Rashesh C Gogri | Managing Director |
| Mr. Harshit M Savla | Joint Managing Director |
| Mr. Harit P Shah | Executive Director |
| Mr. Uday M Patil | Executive Director |
| Mr. Narendra J Salvi | Non Executive Director |
| Mr. Ankit V Paleja | Independent Director |
| Prof. Bhaskar N Thorat | Independent Director |
| Mrs. Neha R Gada | Independent Director |
| Mr. Hasmukh B Dedhia | Independent Director |
| Mr. Sandeep M Joshi | Independent Director |
| Mr. Ajit E Venugopalan | Independent Director |
FAQ
What is the intrinsic value of Aarti Drugs Limited?
Aarti Drugs Limited's intrinsic value (as of 12 December 2025) is 289.67 which is 26.48% lower the current market price of 394.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,595 Cr. market cap, FY2025-2026 high/low of 575/312, reserves of ₹1,250 Cr, and liabilities of 2,245 Cr.
What is the Market Cap of Aarti Drugs Limited?
The Market Cap of Aarti Drugs Limited is 3,595 Cr..
What is the current Stock Price of Aarti Drugs Limited as on 12 December 2025?
The current stock price of Aarti Drugs Limited as on 12 December 2025 is 394.
What is the High / Low of Aarti Drugs Limited stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarti Drugs Limited stocks is 575/312.
What is the Stock P/E of Aarti Drugs Limited?
The Stock P/E of Aarti Drugs Limited is 18.9.
What is the Book Value of Aarti Drugs Limited?
The Book Value of Aarti Drugs Limited is 147.
What is the Dividend Yield of Aarti Drugs Limited?
The Dividend Yield of Aarti Drugs Limited is 0.25 %.
What is the ROCE of Aarti Drugs Limited?
The ROCE of Aarti Drugs Limited is 13.5 %.
What is the ROE of Aarti Drugs Limited?
The ROE of Aarti Drugs Limited is 13.0 %.
What is the Face Value of Aarti Drugs Limited?
The Face Value of Aarti Drugs Limited is 10.0.